NCT05851066View on ClinicalTrials.gov

A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

May 7, 2024

Study Completion Date

May 7, 2024

Conditions
DyslipidemiasFamilial HypercholesterolemiaHypertriglyceridemia
Interventions
DRUG

VSA003

sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg

DRUG

0.9% NaCl

placebo

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Visirna Therapeutics HK Limited

INDUSTRY

NCT05851066 - A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers | Biotech Hunter | Biotech Hunter